Bak has been shown to both promote apoptosis and to inhibit cell death while two other members of the Bcl-2 family of proteins, Bcl-X L and Bcl-2 delay apoptosis induced by various stimuli including chemotherapeutic agents. We generated clones with stable expression of Bak wild-type (wt) and Bak with its BH3 (D78-86) domain deleted (DBH3) in FL5.12 cells or FL5.12 cells expressing either Bcl-X L or Bcl-2 to determine if Bak could accelerate apoptosis and antagonize the death repressor activity of Bcl-X L and Bcl-2 during chemotherapy-induced apoptosis. We found that Bak accelerated cell death in FL5.12 cells treated with etoposide, uorouracil or taxol. In FL5.12 cells expressing Bcl-X L and Bak wt or Bak DBH3, both Bak wt or Bak DBH3 were able to antagonize the protective eect of Bcl-X L when treated with etoposide or¯uorouracil. Bak wt or Bak DBH3 were also able to abrogate the protective eect of Bcl-2 in cells expressing Bcl-2 and Bak wt or Bak DBH3 when challenged by etoposide or¯uorouracil. Immunoprecipitation studies revealed that deletion of BH3 disrupted heterodimerization between Bak and Bcl-X L and that both Bak wt and Bak DBH3 failed to interact with Bcl-2. These results demonstrate that Bak does not require its BH3 domain to promote apoptosis in stably transfected cells. Furthermore, Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-X L and Bcl-2.
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Keywords: Bak; Bcl-X L ; Bcl-2; apoptosis; chemotherapy; cell death Apoptosis, a morphologically distinguished form of programmed cell death, is critical not only during tumorigenesis, tumor progression and treatment resistance, but also plays a role in the pathogenesis of various other diseases including autoimmune disease, viral infection, and neurodegenerative disorders (Ra, 1992; Thompson, 1995; White, 1996) . Moreover, many chemotherapy drugs used to treat cancers are thought to destroy tumor cells through activation of apoptosis (Eastman, 1990; Miyashita and Reed, 1993) . The Bcl-2 family of proteins share conserved regions termed Bcl-2 homology domain 1, 2, and 3 (BH1, BH2, and BH3) (Chittenden et al., 1995b; Yin et al., 1994) . Bcl-2 and its functional homologue, Bcl-X L (Boise et al., 1993) both block apoptosis induced by a variety of cell death signals including chemotherapy drugs (Minn et al., 1995; Miyashita and Reed, 1993) . Bak and Bax, two other members of the Bcl-2 family of proteins, have been shown to both accelerate and block apoptosis (Chittenden et al., 1995a; Farrow et al., 1995; Kiefer et al., 1995; Middleton et al., 1996; Oltvai et al., 1993) . Interestingly, Bak was able to delay cell death in WI-L2 cells upon serum withdrawal and treatment with menadione (Kiefer et al., 1995) while Bax was able rescue populations of sensory neurons deprived of nerve growth factor (Middleton et al., 1996) . Little is known about the role of Bak in the regulation of cell death. Reduced expression of Bak with elevated expression of Bcl-X L in primary colorectal carcinomas has been suggested to occur as an early tumorigenic event leading to tumor progression (Krajewska et al., 1996) .
We developed cell clones with stable expression of HA-tagged Bak wt or HA-tagged Bak DBH3 in the lymphoid cell line, FL5.12, to determine if the BH3 domain is required for Bak to accelerate chemotherapy-induced cell death (Figure 1a ). Dose-response experiments determined that 20 mg/ml of etoposide, 10 mg/ml of¯uorouracil or 0.01 mg/ml of taxol were optimal for Bak wt to accelerate cell death induced by these chemotherapeutic agents compared to the Neo control cell line. As seen in Figures 1b, c and d, wildtype and BH3 deletion mutant Bak clones were all able to accelerate etoposide,¯uorouracil and taxol induced apoptosis in the absence of exogenous Bcl-X L or Bcl-2 expression. FL5.12 cells express nearly undetectable endogenous levels of Bcl-X L or Bcl-2 protein and their endogenous expression does not change after treatment with these antitumor agents in these lymphoid cells (data not shown). Bax wt and Bak wt clones with similar levels of expression also had nearly identical rates of apoptosis (Figure 1) . Therefore, Bak does not require its BH3 domain to accelerate apoptosis induced by etoposide,¯uorouracil and taxol in the absence of Bcl-X L or Bcl-2 in FL5.12 lymphoid cells.
To determine if Bak requires its BH3 domain to antagonize the protective eects of Bcl-X L upon chemotherapy-induced apoptosis, we transfected HAtagged bak wt and HA-tagged bak DBH3 constructs into a FL5.12 cell clone stably expressing FLAGtagged Bcl-X L . Two representative clones, each coexpressing FLAG Bcl-X L and HA Bak wt or HA Bak DBH3, were selected for further study ( Figure 2a Immunoprecipitation studies were performed to con®rm that Bak requires its BH3 domain to form heterodimers with Bcl-X L . As seen in Figure 3 , the HA Bak DBH3 clones failed to associate with FLAG Bcl-X L indicating that the BH3 domain is required for Bak to heterodimerize with Bcl-X L . Therefore, Bak was able to promote etoposide and uorouracil-induced cell death independently of its association with Bcl-X L .
HA-tagged Bak wt and Bak DBH3 constructs were transfected into a FL5.12 cell clone stably expressing FLAG Bcl-2 to determine if Bak could antagonize the protective eects of Bcl-2 upon chemotherapy-induced (amino acids 78-86) in Bak was constructed by a two-step PCR mutagenesis method previously described (Simonian et al., 1996) . Proteins were immunoblotted with anti-HA mAb. Figure 4a , two clones of each, HA Bak wt and Bak DBH3, all with similar levels of protein expression were chosen for further study. Time course experiments using etoposide and¯uorouracil showed that both Bak wt and Bak DBH3 were able to antagonize the protective eects of Bcl-2 and accelerate apoptosis induced by these antitumor agents when compared to the parent FL5.12.FLAG-Bcl-2 cells (Figures 4b and c) . As with Bcl-X L , protection from chemotherapy-induced apoptosis aorded by the Bcl-2 parent cell line was unchanged following transfection, selection in hygromycin and expression of the lacZ gene compared to untransfected Bcl-X L cells (data not shown) indicating that the chemotherapy-induced acceleration of cell death in these experiments was speci®c for Bak expression. Immunoprecipitation studies revealed that HA Bak wt and HA Bak DBH3 6 cells) from the cell extracts used in the immunoprecitation experiments depicted in 3(a) were immunoblotted using anti-FLAG mAb. C1 and C2 are the lysates used in the control immunoprecipitations using a non-speci®c IgG2b (isotype-matched) mAb. C3 represents total lysate from FL5.12 cells expressing FLAG Bcl-X L . (d) Lysates (16 10 6 cells) from the cell extracts used in the immunoprecitation experiments depicted in 3(b) were immunoblotted using anti-HA mAb. C1 and C2 are the lysates used in the control immunoprecipitations using a non-speci®c IgG1 (isotypematched) mAb. C3 represents total lysate from FL5.12 cells expressing HA Bak wt. C4 represents total lysate from FL5.12 cells expressing HA Bax wt failed to associate with FLAG Bcl-2 under conditions where Bax and Bcl-2 formed heterodimers ( Figure 5 ). These studies suggest that Bak does not require BH3 to promote cell death protected by Bcl-2 and that heterodimerization is not required for Bak to antagonize the death-repressor activity of Bcl-2.
In the present study, we demonstrate that Bak can accelerate the rate of apoptosis and antagonize the death-suppressing activity of Bcl-X L and Bcl-2. More importantly, we provide evidence that the interaction between Bak and Bcl-X L and Bcl-2 is not required for Bak to exert its death-accelerating activity during apoptosis mediated by chemotherapeutic agents. Bak was unable to completely abrogate the protection aorded by Bcl-X L and Bcl-2 upon induction of cell death as we previously reported for Bax (Simonian et al., 1996) . The precise mechanism(s) whereby Bak antagonizes both Bcl-X L and Bcl-2 and promote cell death independently of its association with these (1610 6 cells) from the cell extracts used in the immunoprecitation experiments depicted in 5(a) were immunoblotted using anti-FLAG mAb. C1 and C2 are the lysates used in the control immunoprecipitations using a non-speci®c IgG2b (isotype-matched) mAb. C3 represents total lysate from FL5.12 cells expressing FLAG Bcl-2. (d) Lysates (1610 6 cells) from the cell extracts used in the immunoprecipitation experiments depicted in (b) were immunoblotted using anti-HA mAb. C1 and C2 are the lysates used in the control immunoprecipitations using a non-speci®c IgG1 (isotype-matched) mAb. C3 represents total lysate from FL5.12 cells expressing HA Bax wt. C4 represents total lysate from FL5.12 cells expressing HA Bak wt survival proteins is unclear. Bak could act upstream of Bcl-2 and Bcl-X L and promote cell death by enhancing death signals which can be inhibited by these survival proteins. An alternative explanation is that Bak promotes cell death and antagonize Bcl-2 and Bcl-X L through competition or sequestration for cellular factors. The identity of these putative cellular factor(s) remains to be elucidated. A potential candidate is BID since it interacts with Bcl-2, Bcl-X L and Bax (Wang et al., 1996) . Furthermore, BID has been proposed to serve as a death ligand for Bax which may be sequestered by overexpression of Bcl-X L or Bcl-2 and represent a cellular factor which links the Bcl-2 family of proteins and the executioners of cell death, the cysteine proteases (Wang et al., 1996) .
Regulation of cell death by Bcl-2 family members appears to depend in part on the relative levels and competing dimerizations of dierent Bcl-2 homologs. Two distinct mechanisms could be proposed to explain the regulation of cell death by Bcl-2 family members. First, death-promoting Bak and Bax can antagonize Bcl-2 homologs Bcl-2 and Bcl-X L independently of heterodimerization by enhancing death signals or perhaps through competition for cellular factors. Second, susceptibility to cell death can be controlled through heterodimerization between death-promoting and death-suppressing Bcl-2 homologs. The latter mechanism would regulate the amounts of free Bax/ Bak or Bcl-2/Bcl-X L and in¯uence susceptibility to cell death depending on the relative levels of these proteins. Similar rates of apoptosis were observed when FL5.12 cells expressing similar levels of Bak and Bax as well as exogenous Bcl-X L protein were treated with etoposide or¯uorouracil. However, lower expression of Bak DBH3 was not able to antagonize the protective eects of Bcl-X L to the same extent as Bak wt. In the absence of Bcl-2 or Bcl-X L , similar levels of Bak and Bak DBH3 protein conferred nearly identical rates of cell death induced by chemotherapeutic agents. These ®ndings suggest that although Bak and Bcl-X L inhibit the function of each other through heterodimerization, a dimerization-independent mechanism is also important for regulation of cell death.
Although Bak and Bax require their BH3 domains to associate with Bcl-X L , they do not require their BH3 domains nor heterodimerization with Bcl-X L and Bcl-2 to promote cell death induced by chemotherapeutic agents in FL5.12 lymphoid cells (Simonian et al., 1996) . In another study, however, Bak and Bax required BH3 to interact with Bcl-X L and also to induce cell death by transient transfection assays using Rat-1 ®broblasts (Chittenden et al., 1995a) . Several possibilities may explain the apparent discrepancy between the present results and those obtained by other investigators. First, the BH3 deletion mutant of Bax or Bak may have a dierential eect on cell death depending on the cell line used for study. For example, the observation that Bak and Bax can act as both facilitator and inhibitor of cell death suggests that cell type-speci®c expression of certain factors plays a role in determining biological activity (Kiefer et al., 1995; Middleton et al., 1996) . Second, our analysis was performed in stable cell lines where induction of cell death required a speci®c apoptotic stimulus whereas the function of Bak and Bax in previous studies was determined in transient assays where the amount of proteins expressed by the cells could not be determined. It is possible, therefore, that the type of apoptotic signal or the level of gene expression is critical for the biological function observed in various systems.
